Publications by authors named "Raoul Tibes"

Claim this Profile
P
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Raoul Tibes, Heidi E Kosiorek, Amylou C Dueck, Jeanne Palmer, Lisa Sproat

Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, Wafa Al-Santli, Hua Zhou, Raoul Tibes

Cancer Discov· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
Aref Al-Kali, Raoul Tibes, Pamela Atherton, Jeanne Palmer, Hassan B Alkhateeb

Am J Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Tamara K Moyo, Jason H Mendler, Raphael Itzykson, Ashwin Kishtagari, Eric Solary, Raoul Tibes

BMC Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms.
Sabrina Kraus, Alexander Dierks, Leo Rasche, Olivia Kertels, Malte Kircher, Raoul Tibes

J Nucl Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
Andoni Garitano-Trojaola, Ana Sancho, Ralph Götz, Patrick Eiring, Susanne Walz, Raoul Tibes

Commun Biol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin.
Andres M Arias Lorza, Harshan Ravi, Rohit C Philip, Jean-Philippe Galons, Theodore P Trouard, Raoul Tibes

Sci Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
Alessandro Rambaldi, Alessandra Iurlo, Alessandro M Vannucchi, Richard Noble, Nikolas von Bubnoff, Raoul Tibes

Leukemia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Triazolo[4,5-]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells" [Comput. Struct. Biotechnol. J. 16 (2018) 350-360].
Lea Lough, Dan Sherman, Manuel Becerra-Flores, Deepika Vasudevan, Olga Lavinda, Raoul Tibes

Comput Struct Biotechnol J· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
Jun H Choi, James M Bogenberger, Raoul Tibes

Target Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.
Raoul Tibes, James M Bogenberger

Front Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
Hani M Babiker, Sara A Byron, William P D Hendricks, William F Elmquist, Gautham Gampa, Raoul Tibes

Invest New Drugs· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Xufeng Chen, Christina Glytsou, Hua Zhou, Sonali Narang, Denis E Reyna, Raoul Tibes

Cancer Discov· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Guillermo Garcia-Manero, Gail Roboz, Katherine Walsh, Hagop Kantarjian, Ellen Ritchie, Raoul Tibes

Lancet Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.
Eric Wang, Sydney X Lu, Alessandro Pastore, Xufeng Chen, Jochen Imig, Raoul Tibes

Cancer Cell· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
Joshua F Zeidner, Matthew C Foster, Amanda L Blackford, Mark R Litzow, Lawrence E Morris, Raoul Tibes

Leuk Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triazolo[4,5]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce Growth of Leukemia Cells.
Lea Lough, Dan Sherman, Manuel Beccera-Flores, Olga Lavinda, Eric Ni, Raoul Tibes

Comput Struct Biotechnol J· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Eytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, Raoul Tibes, Jesus G Berdeja

Blood· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
Raoul Tibes, Mitesh J Borad, Corina E Dutcus, Larisa Reyderman, Kevie Feit

Br J Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All Thiopurines Are Equal But Some Thiopurines Are More Equal Than Others-Reply.
Raoul Tibes, Nathalie Ertz-Archambault, Heidi Kosiorek

JAMA Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined venetoclax and alvocidib in acute myeloid leukemia.
James Bogenberger, Clifford Whatcott, Nanna Hansen, Devora Delman, Chang-Xin Shi, Raoul Tibes

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
Kebede Begna, Aref Al-Kali, Michelle Elliott, James Foran, Naseema Gangat, Raoul Tibes

Am J Hematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
Benjamin H Durham, Bartlomiej Getta, Sascha Dietrich, Justin Taylor, Helen Won, Raoul Tibes

Blood· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Hagop M Kantarjian, Gail J Roboz, Patricia L Kropf, Karen W L Yee, Casey L O'Connell, Raoul Tibes

Lancet Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Jonathan A Webster, Raoul Tibes, Larry Morris, Amanda L Blackford, Mark Litzow

Leuk Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis